Pay in 4 interest-free payments of $7.40 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
If you take GLP-1s, monitor yourself for mood changes
ATTAIN-1 (NCT05869903) was a Phase III, 72-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of orforglipron at various doses to placebo in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease, who did not have diabetes
[1] [2] As with any medication, understanding the full safety profile, including potential effects on renal health, is essential for appropriate patient counseling and monitoring
Patients enrolled in Medicare who are diagnosed with obesity and related comorbidities will have a co-pay of $50 per month for Wegovy and Zepbound
Always follow your healthcare professional's specific guidance regarding your complete medication regimen
doi: 10.1007/s12602-025-10559-6 124 BonfantiA
US$ 27.12
US$ 28.80
US$ 21.38
US$ 23.23
US$ 28.48
